세계의 여성용 건강 진단 시장 : 유형, 용도, 최종 사용자별 예측(2025-2030년)

The Women's Health Diagnostics Market was valued at USD 43.36 billion in 2023, expected to reach USD 46.82 billion in 2024, and is projected to grow at a CAGR of 9.25%, to USD 80.59 billion by 2030.

The Women's Health Diagnostics market is a pivotal segment within healthcare, focusing on diagnostic tools and techniques aimed at detecting and managing health conditions that uniquely or disproportionately affect women, such as breast cancer, osteoporosis, and reproductive health issues. The necessity for these diagnostics arises from the need for timely and accurate detection, which is crucial for effective treatment and management of such conditions. Applications include early-stage cancer detection, prenatal testing, fertility diagnostics, and monitoring of general well-being. The end-use scope covers hospitals, diagnostic laboratories, home care, and specialized clinics dedicated to women's health.

Key factors influencing market growth include increasing awareness about women's health, technological advancements in diagnostic procedures like minimally invasive tests and point-of-care diagnostics, and supportive governmental policies enhancing healthcare infrastructure. Additionally, the rising prevalence of chronic diseases and growing demand for personalized medicine are fueling market expansion. Opportunities lie in the integration of AI and machine learning to refine diagnostic accuracy and the development of home-based diagnostic tools that prioritize convenience and privacy. Companies should focus on expanding access in emerging markets and collaborate with policy makers to enhance awareness and affordability.

Despite these promising opportunities, challenges include high costs associated with advanced diagnostics, regulatory hurdles, and disparities in healthcare access, which may limit market penetration in lower-income regions. Additionally, maintaining data privacy and navigating complex reimbursement landscapes pose significant obstacles.

Innovation can be driven by developing cost-effective diagnostic solutions and investing in research to enhance disease-specific biosensors and biomarkers. Furthermore, leveraging telehealth services to reach underserved populations can create broader market access. Insights on market nature indicate a competitive landscape with rapid technological advancements, requiring companies to remain agile and proactive in R&D investments. Overall, the Women's Health Diagnostics market holds substantial growth potential, but capturing it will require strategic focus on innovation, affordability, and accessibility.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Women's Health Diagnostics Market

The Women's Health Diagnostics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing incantaces of chronic and life-style related disorders in women
  • Rising number of imaging and diagnostic centres across the globe
  • Improved and technically advanced healthcare infastructure
• Market Restraints
  • High cost associated with procedure and diagnostic imaging system
• Market Opportunities
  • Substantial focus on microfluidics and nanotechnology-based POC devices for diagnostic
  • Promising digital technology trends shaping women's health diagnostic
• Market Challenges
  • Dearth of technically skilled healthcare professionals

Porter's Five Forces: A Strategic Tool for Navigating the Women's Health Diagnostics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Women's Health Diagnostics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Women's Health Diagnostics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Women's Health Diagnostics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Women's Health Diagnostics Market

A detailed market share analysis in the Women's Health Diagnostics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Women's Health Diagnostics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Women's Health Diagnostics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Women's Health Diagnostics Market

A strategic analysis of the Women's Health Diagnostics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Women's Health Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AccuBioTech Co., Ltd., Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Biomerieux SA, Cardinal Health, Inc., Carestream Health, Inc., Chembio Diagnostic Systems, Inc., Cook Medical, Inc., Danaher Corporation, DIALAB GmbH, EKF Diagnostics Holdings PLC, F. Hoffmann-La Roche Ltd., FUJIFILM Holdings Corporation, GE Healthcare, Guided Therapeutics, Inc., Hill-Rom Holdings, Inc., Hologic, Inc., Koninklijke Philips N.V., MedGyn Products, Inc., NeuroLogica Corporation, Nova Biomedical, OSI Systems, Inc., Perkinelmer Inc., Quest Diagnostics Incorporated, Sekisui Diagnostics, LLC, Siemens AG, SuperSonic Imagine, Thermo Fisher Scientific Inc., and Werfen, S.A..

Market Segmentation & Coverage

This research report categorizes the Women's Health Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Type, market is studied across Point-of-Care and Self Check.
• Based on Application, market is studied across Breast Cancer Testing, Cervical Cancer Testing, Infectious Disease Testing, Osteoporosis Testing, Ovarian Cancer Testing, Pregnancy & Fertility Testing, Prenatal Genetic Screening & Carrier Testing, Sexually Transmitted Disease Testing, and Ultrasound Tests. The Breast Cancer Testing is further studied across Biopsies, Blood Chemistries & Blood Cell Count Tests, Breast Cancer Tumor Marker Tests, and Mammography. The Cervical Cancer Testing is further studied across HPV Testing and PAP Smear. The Infectious Disease Testing is further studied across HEPAtitis Testing, MRSA Testing, Tuberculosis Testing, and Urinary Tract Infection Testing (Vaginal pH & Vaginitis). The Osteoporosis Testing is further studied across Bone Densitometry and in Vitro Blood Tests. The Ovarian Cancer Testing is further studied across Diagnostic Imaging Tests and Ovarian Cancer Tumor Marker Tests. The Pregnancy & Fertility Testing is further studied across Fertility Monitors, Lab-Based Testing, and Pregnancy Testing & Ovulation Prediction Kits. The Prenatal Genetic Screening & Carrier Testing is further studied across Cystic Fibrosis, Down Syndrome & Edwards Syndrome, and Torch Infections. The Sexually Transmitted Disease Testing is further studied across Chlamydia Trachomatis & Neisseria Gonorrhoeae (CT/NG) Testing and HIV Testing. The Ultrasound Tests is further studied across Breast Imaging and OB/GYN Imaging.
• Based on End-User, market is studied across Diagnostic & Imaging Centers, Home Care, and Hospitals & Clinics.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing incantaces of chronic and life-style related disorders in women
    • 5.1.1.2. Rising number of imaging and diagnostic centres across the globe
    • 5.1.1.3. Improved and technically advanced healthcare infastructure
  • 5.1.2. Restraints
    • 5.1.2.1. High cost associated with procedure and diagnostic imaging system
  • 5.1.3. Opportunities
    • 5.1.3.1. Substantial focus on microfluidics and nanotechnology-based POC devices for diagnostic
    • 5.1.3.2. Promising digital technology trends shaping women's health diagnostic
  • 5.1.4. Challenges
    • 5.1.4.1. Dearth of technically skilled healthcare professionals
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Women's Health Diagnostics Market, by Type

• 6.1. Introduction
• 6.2. Point-of-Care
• 6.3. Self Check

7. Women's Health Diagnostics Market, by Application

• 7.1. Introduction
• 7.2. Breast Cancer Testing
  • 7.2.1. Biopsies
  • 7.2.2. Blood Chemistries & Blood Cell Count Tests
  • 7.2.3. Breast Cancer Tumor Marker Tests
  • 7.2.4. Mammography
• 7.3. Cervical Cancer Testing
  • 7.3.1. HPV Testing
  • 7.3.2. PAP Smear
• 7.4. Infectious Disease Testing
  • 7.4.1. HEPAtitis Testing
  • 7.4.2. MRSA Testing
  • 7.4.3. Tuberculosis Testing
  • 7.4.4. Urinary Tract Infection Testing (Vaginal pH & Vaginitis)
• 7.5. Osteoporosis Testing
  • 7.5.1. Bone Densitometry
  • 7.5.2. in Vitro Blood Tests
• 7.6. Ovarian Cancer Testing
  • 7.6.1. Diagnostic Imaging Tests
  • 7.6.2. Ovarian Cancer Tumor Marker Tests
• 7.7. Pregnancy & Fertility Testing
  • 7.7.1. Fertility Monitors
  • 7.7.2. Lab-Based Testing
  • 7.7.3. Pregnancy Testing & Ovulation Prediction Kits
• 7.8. Prenatal Genetic Screening & Carrier Testing
  • 7.8.1. Cystic Fibrosis
  • 7.8.2. Down Syndrome & Edwards Syndrome
  • 7.8.3. Torch Infections
• 7.9. Sexually Transmitted Disease Testing
  • 7.9.1. Chlamydia Trachomatis & Neisseria Gonorrhoeae (CT/NG) Testing
  • 7.9.2. HIV Testing
• 7.10. Ultrasound Tests
  • 7.10.1. Breast Imaging
  • 7.10.2. OB/GYN Imaging

8. Women's Health Diagnostics Market, by End-User

• 8.1. Introduction
• 8.2. Diagnostic & Imaging Centers
• 8.3. Home Care
• 8.4. Hospitals & Clinics

9. Americas Women's Health Diagnostics Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Women's Health Diagnostics Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Women's Health Diagnostics Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbott Laboratories
• 2. AccuBioTech Co., Ltd.
• 3. Becton, Dickinson and Company
• 4. Bio-Rad Laboratories, Inc.
• 5. Biomerieux SA
• 6. Cardinal Health, Inc.
• 7. Carestream Health, Inc.
• 8. Chembio Diagnostic Systems, Inc.
• 9. Cook Medical, Inc.
• 10. Danaher Corporation
• 11. DIALAB GmbH
• 12. EKF Diagnostics Holdings PLC
• 13. F. Hoffmann-La Roche Ltd.
• 14. FUJIFILM Holdings Corporation
• 15. GE Healthcare
• 16. Guided Therapeutics, Inc.
• 17. Hill-Rom Holdings, Inc.
• 18. Hologic, Inc.
• 19. Koninklijke Philips N.V.
• 20. MedGyn Products, Inc.
• 21. NeuroLogica Corporation
• 22. Nova Biomedical
• 23. OSI Systems, Inc.
• 24. Perkinelmer Inc.
• 25. Quest Diagnostics Incorporated
• 26. Sekisui Diagnostics, LLC
• 27. Siemens AG
• 28. SuperSonic Imagine
• 29. Thermo Fisher Scientific Inc.
• 30. Werfen, S.A.